| In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system D Maddalo, E Manchado, CP Concepcion, C Bonetti, JA Vidigal, YC Han, ... Nature 516 (7531), 423-427, 2014 | 711 | 2014 |
| Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling S Weissmueller, E Manchado, M Saborowski, JP Morris, E Wagenblast, ... Cell 157 (2), 382-394, 2014 | 514 | 2014 |
| A combinatorial strategy for treating KRAS-mutant lung cancer E Manchado, S Weissmueller, JP Morris, CC Chen, R Wullenkord, ... Nature 534 (7609), 647-651, 2016 | 408 | 2016 |
| Genomic stability and tumour suppression by the APC/C cofactor Cdh1 I García-Higuera, E Manchado, P Dubus, M Cañamero, J Méndez, ... Nature cell biology 10 (7), 802-811, 2008 | 385 | 2008 |
| NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination M Ruscetti, J Leibold, MJ Bott, M Fennell, A Kulick, NR Salgado, CC Chen, ... Science 362 (6421), 1416-1422, 2018 | 284 | 2018 |
| Killing cells by targeting mitosis E Manchado, M Guillamot, M Malumbres Cell Death & Differentiation 19 (3), 369-377, 2012 | 266 | 2012 |
| Targeting mitotic exit leads to tumor regression in vivo: Modulation by Cdk1, Mastl, and the PP2A/B55α, δ phosphatase E Manchado, M Guillamot, G de Cárcer, M Eguren, M Trickey, ... Cancer cell 18 (6), 641-654, 2010 | 222 | 2010 |
| Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer KP O'Rourke, E Loizou, G Livshits, EM Schatoff, T Baslan, E Manchado, ... Nature biotechnology 35 (6), 577-582, 2017 | 218 | 2017 |
| Kinase regulation of human MHC class I molecule expression on cancer cells EJ Brea, CY Oh, E Manchado, S Budhu, RS Gejman, G Mo, P Mondello, ... Cancer immunology research 4 (11), 936-947, 2016 | 157 | 2016 |
| The anaphase-promoting complex/cyclosome (APC/C): cell-cycle-dependent and-independent functions E Manchado, M Eguren, M Malumbres Biochemical Society Transactions 38 (1), 65-71, 2010 | 143 | 2010 |
| Conditional reverse tet-transactivator mouse strains for the efficient induction of TRE-regulated transgenes in mice LE Dow, Z Nasr, M Saborowski, SH Ebbesen, E Manchado, N Tasdemir, ... PloS one 9 (4), e95236, 2014 | 93 | 2014 |
| Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer M Álvarez-Fernández, M Sanz-Flores, B Sanz-Castillo, M Salazar-Roa, ... Cell Death & Differentiation, 1-13, 2017 | 90 | 2017 |
| Non-mitotic functions of the Anaphase-Promoting Complex M Eguren, E Manchado, M Malumbres Seminars in cell & developmental biology 22 (6), 572-578, 2011 | 82 | 2011 |
| SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors H Lu, C Liu, R Velazquez, H Wang, LM Dunkl, M Kazic-Legueux, ... Molecular cancer therapeutics 18 (7), 1323-1334, 2019 | 76 | 2019 |
| The APC/C cofactor Cdh1 prevents replicative stress and p53-dependent cell death in neural progenitors M Eguren, E Porlan, E Manchado, I García-Higuera, M Cañamero, ... Nature communications 4 (1), 1-16, 2013 | 58 | 2013 |
| Cdc14b regulates mammalian RNA polymerase II and represses cell cycle transcription M Guillamot, E Manchado, M Chiesa, G Gómez-López, DG Pisano, ... Scientific reports 1 (1), 189, 2011 | 56 | 2011 |
| USP39 deubiquitinase is essential for KRAS oncogene-driven cancer JM Fraile, E Manchado, A Lujambio, V Quesada, D Campos-Iglesias, ... Journal of Biological Chemistry 292 (10), 4164-4175, 2017 | 41 | 2017 |
| Targeting aneuploidy for cancer therapy E Manchado, M Malumbres Cell 144 (4), 465-466, 2011 | 31 | 2011 |
| 4th, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T, Aust D, Markert EK, Wu J, et al. Mutant p53 drives pancreatic cancer metastasis through cell … S Weissmueller, E Manchado, M Saborowski, JP Morris Cell 157, 382-94, 2014 | 22 | 2014 |
| A pipeline for drug target identification and validation E Manchado, CH Huang, N Tasdemir, DF Tschaharganeh, JE Wilkinson, ... Cold Spring Harbor symposia on quantitative biology 81, 257-267, 2016 | 17 | 2016 |
Marcos MalumbresVall d'Hebron Institute of OncologyVerified email at vhio.net
